Previous clinical, observation and epidemiologic studies have demonstrated strong association between serum uric acid SUA and cardiovascular disease hypertension, heart failure, asymptomatic atherosclerosis , metabolic states abdominal obesity, diabetes mellitus, metabolic syndrome, insulin resistance and kidney disease. There is a large body of evidence regarding the role of SUA as predictor of CV events and CV mortality in general population and individuals with established CV disease and metabolic diseases. However, SUA may exhibit protective effects on endothelium and vasculature as well as attenuate endogenous repair system through mobbing and differentiation of cell precursors. Although SUA lowering drugs are widely used in patients with symptomatic hyperuricemia and gout beyond their etiologies, there is no agreement of SUA below target level 6.0 mg/dL in asymptomatic individuals with kidney injury and CV disease and data of ones are sufficiently limited. The short communication is depicted on the controversial role of SUA as primary cell toxicity agent and secondary cell protector against hypoxia, ischemia and apoptosis.
Serum uric acid cardiovascular disease metabolic states outcomes biomarker
Birincil Dil | İngilizce |
---|---|
Bölüm | Research Article |
Yazarlar | |
Yayımlanma Tarihi | 1 Temmuz 2017 |
Yayımlandığı Sayı | Yıl 2017 |